Real-time Estimate
Cboe BZX
11:11:31 08/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
4.745
USD
|
+0.32%
|
|
+0.11%
|
+4.74%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
955.1
|
440.9
|
246.2
|
355.7
|
431.1
|
-
|
-
|
Enterprise Value (EV)
1 |
955.1
|
440.9
|
246.2
|
355.7
|
431.1
|
431.1
|
431.1
|
P/E ratio
|
-6.03
x
|
-3.38
x
|
-1.99
x
|
-2.56
x
|
-3.1
x
|
-2.88
x
|
-3.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
43.1
x
|
8.6
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
43.1
x
|
8.6
x
|
EV / EBITDA
|
-15.2
x
|
-3.43
x
|
-1.72
x
|
-2.51
x
|
-2.38
x
|
-2.08
x
|
-
|
EV / FCF
|
-17.8
x
|
-4.09
x
|
-2
x
|
-2.93
x
|
-3.48
x
|
-2.94
x
|
-2.81
x
|
FCF Yield
|
-5.61%
|
-24.4%
|
-49.9%
|
-34.1%
|
-28.8%
|
-34%
|
-35.6%
|
Price to Book
|
2.77
x
|
1.91
x
|
1.22
x
|
1.37
x
|
1.73
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
38,158
|
38,375
|
47,630
|
78,338
|
91,141
|
-
|
-
|
Reference price
2 |
25.03
|
11.49
|
5.170
|
4.540
|
4.730
|
4.730
|
4.730
|
Announcement Date
|
25/03/21
|
01/03/22
|
06/03/23
|
26/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
10
|
50.16
|
EBITDA
1 |
-
|
-62.8
|
-128.6
|
-143.5
|
-141.6
|
-181.2
|
-207.3
|
-
|
EBIT
1 |
-
|
-63.47
|
-130.7
|
-145.6
|
-143.7
|
-159.1
|
-190.5
|
-190.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,904.34%
|
-379.72%
|
Earnings before Tax (EBT)
1 |
-
|
-63.41
|
-130.3
|
-141.9
|
-134.2
|
-152.3
|
-211.4
|
-228.5
|
Net income
1 |
-
|
-70.34
|
-130.3
|
-141.9
|
-134.2
|
-150.8
|
-185
|
-185.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,849.36%
|
-369.19%
|
EPS
2 |
-88.28
|
-4.150
|
-3.400
|
-2.600
|
-1.770
|
-1.524
|
-1.643
|
-1.568
|
Free Cash Flow
1 |
-
|
-53.55
|
-107.8
|
-122.8
|
-121.3
|
-123.9
|
-146.4
|
-153.4
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,463.83%
|
-305.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/20
|
25/03/21
|
01/03/22
|
06/03/23
|
26/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-36.95
|
-34.91
|
-36.87
|
-
|
-
|
-40.71
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-35.68
|
-37.46
|
-35.43
|
-37.41
|
-36.07
|
-36.7
|
-41.24
|
-37.69
|
34.78
|
-30.01
|
-32.69
|
-35.43
|
-42.13
|
-48.15
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-35.6
|
-37.37
|
-35.37
|
-37.14
|
-35.05
|
-34.38
|
-38.68
|
-35.19
|
-32.48
|
-27.89
|
-32.32
|
-35.4
|
-40.96
|
-43.81
|
Net income
1 |
-35.6
|
-37.37
|
-35.37
|
-37.14
|
-35.05
|
-34.38
|
-38.68
|
-35.19
|
-32.48
|
-27.89
|
-31.43
|
-34.15
|
-40.02
|
-45.38
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9300
|
-0.9700
|
-0.9200
|
-0.9600
|
-0.5100
|
-0.4800
|
-0.5200
|
-0.4700
|
-0.4300
|
-0.3600
|
-0.3325
|
-0.3493
|
-0.3977
|
-0.4187
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
01/03/22
|
09/05/22
|
08/08/22
|
03/11/22
|
06/03/23
|
08/05/23
|
07/08/23
|
13/11/23
|
26/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-53.6
|
-108
|
-123
|
-121
|
-124
|
-146
|
-153
|
ROE (net income / shareholders' equity)
|
-
|
-57.7%
|
-17.3%
|
-61.3%
|
-55.7%
|
-59.4%
|
-52.7%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-34.7%
|
-15.5%
|
-49.6%
|
-46.1%
|
-35.5%
|
-43.9%
|
-
|
Assets
1 |
-
|
202.9
|
841.1
|
286.1
|
291.4
|
424.9
|
421.6
|
-
|
Book Value Per Share
2 |
-
|
9.020
|
6.010
|
4.230
|
3.310
|
2.740
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-2.770
|
-2.130
|
-1.600
|
-1.370
|
-1.230
|
-
|
Capex
1 |
-
|
-
|
1.65
|
6.53
|
0.19
|
1.03
|
1.37
|
1.61
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
13.67%
|
3.21%
|
Announcement Date
|
26/02/20
|
25/03/21
|
01/03/22
|
06/03/23
|
26/03/24
|
-
|
-
|
-
|
Last Close Price
4.73
USD Average target price
15.17
USD Spread / Average Target +220.65% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.74% | 431M | | -2.35% | 89.33B | | +4.08% | 41.19B | | -14.69% | 31.87B | | +53.68% | 24.52B | | -14.59% | 15.68B | | -8.63% | 12.34B | | -40.39% | 12.23B | | +6.22% | 8.83B | | -6.43% | 8.28B |
Biopharmaceuticals
|